Cary Grace: I would say what we look at is both. And so you should expect us to look at solutions that are going to mirror what we’re seeing and anticipate to see in terms of future client needs, tech enabled solutions, language services. And what we did there is probably a great example of what we would continue to look for in the future. And then when we look at areas like what James was just talking about and where we think we have an opportunity to accelerate demand, we will always look at those areas as well. Jeff, what would you add about M&A overall?
Jeff Knudson: I think the pipeline right now, I would say is we’re starting to see more tech-enabled assets. That market has been pretty slow the last 18 months. So we’re seeing activity pick up there as well as within James’s area on the POS side, not as much in the pipeline on the Travel Nurse or Allied side.
William Sutherland: Okay. Thanks, everybody.
Operator: Thank you. One moment for our final question here. This question is from Andre Childress of Baird.
Andre Childress: Hey, this is Andre on from Mark Marcon. Thank you for taking our questions. So I’ll just have one quick follow-up on the last comment you made with the tech-enabled assets. Can you first talk about some of the multiple revaluations you’re seeing on some of those companies that are for sale, and then also additionally on capital allocation? Can you talk about maybe your appetite for further share repurchases and how you view your leverage ratio? Thanks.
Cary Grace: Andre, let me take the first part of that, and then I’ll let Jeff talk about repurchases. What we are hearing is that on some of the tech-enabled solutions, there is an expectation as we get through the year that there’s a bit of an understanding that some of those assets have been revalued, since what we might have seen. So while we haven’t seen a number of those assets trade over the past couple quarters. We would expect that there would be some expectations that those valuations would look more like what you’ve seen the broader market trade at. So our expectation is we not only see more, but we’d see valuation levels that could make it interesting. On the repurchase side, Jeff, I’ll let you talk.
Jeff Knudson: Yes, I would just say, Andre, obviously the balance sheet affords us a tremendous amount of flexibility right now levered at 1.5x. We did enter into the $200 million ASR this quarter. That could on an outside date, be completed as late as November or as early at the counterparties discretion sometime in the third quarter. So, again, that brought our full-year share repurchase — in year share repurchases to $425 million. We think that’s pretty close to the right number for calendar ’23. And then moving into ’24 and beyond, obviously, M&A would be our first priority for capital deployment. And then apps and anything compelling on the M&A front, we will look to return capital to shareholders and repurchase shares.
Andre Childress: Great. Thank you for all the color.
Operator: Okay. Thank you for your question. Seeing no further questions at this time, I would now like to turn the conference back to Cary Grace for closing comments.
Cary Grace: I appreciate that. I always thank our amazing AMN team members and clinicians, and I just want to leave by calling out for a special thank you to Landry and Denise in what they did to build AMN into the incredible company it is today. And a huge congratulations to Robin and Whitney on their new roles. As always, we appreciate your interest in AMN. Thank you all.
Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.
